文献速递其他结缔组织病

系统性硬化症早发患者克隆性造血增加

Clonal haematopoiesis is increased in early onset in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

结果显示SSc患者与健康供者总体CHIP患病率无显著差异,但50岁以下SSc患者CHIP患病率显著高于同龄健康供者。

要点

  • SSc患者与健康供者总体CHIP患病率无显著差异(14% vs 9%,P=0.58)。
  • 50岁以下SSc患者CHIP患病率显著高于同龄健康供者(25% vs 4%,P=0.045)。
  • 有无CHIP的SSc患者之间未观察到主要临床差异。

核心结论

  • SSc患者总体CHIP患病率与健康供者无显著差异,但年轻SSc患者CHIP患病率显著升高。
  • CHIP是增加SSc发病风险还是SSc相关骨髓微环境改变的结果,尚待进一步探索。

研究设计与样本

  • 比较SSc患者与健康供者CHIP患病率,并分析CHIP与SSc临床表型的关联。

主要发现

  • 13/90例SSc患者(14%)检出15个体细胞变异,4/44名健康供者(9%)检出4个体细胞变异(P=0.58)。
  • 50岁以下SSc患者CHIP患病率为25%(6/24),健康供者为4%(1/26)(P=0.045)。
  • 60岁以下SSc患者CHIP患病率为17%(7/42),健康供者为3%(1/38)(P=0.065)。
  • 70岁以上SSc患者与健康供者的CHIP患病率相似。
  • 最常见突变为DNMT3A(7个变异)。

关键数值与推荐

  • CHIP在50岁以下SSc患者中为25%(6/24),健康供者为4%(1/26),P=0.045。
  • CHIP在60岁以下SSc患者中为17%(7/42),健康供者为3%(1/38),P=0.065。
  • SSc患者总体CHIP患病率为14%(13/90),健康供者为9%(4/44),P=0.58。

临床怎么用

  • 对年轻SSc患者可关注CHIP相关克隆性造血,但本研究未显示其与主要临床表型的关联。
  • CHIP与SSc的因果关系尚未明确,临床决策中不宜据此改变管理策略。

局限性

  • 样本量较小(90例SSc患者和44名健康供者),可能影响统计效能。
  • CHIP与SSc发病的因果关系及骨髓微环境机制尚未阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SSc is an autoimmune disease characterized by fibrosis, microangiopathy and immune dysfunctions including dysregulation of proinflammatory cytokines. Clonal haematopoiesis of indeterminate potential (CHIP) is defined by the acquisition of somatic mutations in haematopoietic stem cells leading to detectable clones in the blood. Recent data have shown a higher risk of cardiovascular disease in patients with CHIP resulting from increased production of proinflammatory cytokines and accelerated atherosclerosis. Eventual links between CHIP and autoimmune diseases are undetermined. The aim of our study was to evaluate the prevalence of CHIP in SSc patients and its association with clinical phenotype. METHODS: Forty-one genes frequently mutated in myeloid malignancies were sequenced in peripheral blood mononuclear cells from 90 SSc patients and 44 healthy donors. RESULTS: A total of 15 somatic variants were detected in 13/90 SSc patients (14%) and four somatic variants in 4/44 (9%) healthy donors (HD) (P = 0.58). The prevalence of CHIP was significantly higher in younger SSc patients than in HD: 25% (6/24) vs 4% (1/26) (P = 0.045) under 50 years and 17% (7/42) vs 3% (1/38) (P = 0.065) under 60 years. The prevalence of CHIP in patients over 70 years was similar in SSc patients and healthy donors. The most common mutations occurred in DNMT3A (seven variants). No major clinical differences were observed between SSc patients with or without CHIP. CONCLUSION: Whether CHIP increases the risk to develop SSc or is a consequence of a SSc-derived modified bone marrow micro-environment remains to be explored.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ricard L, Hirsch P, Largeaud L, et al. Clonal haematopoiesis is increased in early onset in systemic sclerosis. Rheumatology (Oxford). 2020. PMID: 32757002. doi:10.1093/rheumatology/keaa282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。